Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

ABSTRACT: BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

PROVIDER: PRJNA765322 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16009442_1.fastq.gz	Fastqsanger.gz
	SRR16009442_2.fastq.gz	Fastqsanger.gz
	SRR16009443_1.fastq.gz	Fastqsanger.gz
	SRR16009443_2.fastq.gz	Fastqsanger.gz
	SRR16009444_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 34

Similar Datasets

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

| PRJNA765320 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

| PRJNA765317 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well as enhance anti-tumor immunity and augment cancer immunotherapies. By screening a small molecule library of epigenetics-based therapeutics, BET bromodomain inhibitors (BETi) were identified as agents that sensitize tumor cells to the anti-tumor activity of CD8+ T-cells. BETi modulated tumor cells to be sensitized to the cytotoxic effects of the pro-inflammatory cytokine TNF. By preventing the recruitment of BRD4 to p65-bound cis-regulatory elements, BETi suppressed the induction of inflammatory gene expression, including the key NF-B target genes BIRC2 (cIAP1) and BIRC3 (cIAP2). Disruption of pro-survival NF-B signaling by BETi led to unrestrained TNF-mediated activation of the extrinsic apoptotic cascade and tumor cell death. Administration of BETi in combination with T-cell bispecific (TCB) antibodies increased bystander killing of tumor cells and enhanced tumor growth inhibition in vivo in a TNF-dependent manner. This novel epigenetic mechanism of immunomodulation may guide future use of BETi as adjuvants for immune oncology agents.

2021-09-24 | GSE184589 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]

2021-09-24 | GSE184591 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-09-24 | GSE184592 | GEO

FTO degradation targeting enhances anti-tumor immunity

Project description:FTO degradation targeting enhances anti-tumor immunity

| PRJNA1053378 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

| PRJNA778073 | ENA

T-bet regulated genes in KG1 cells

Project description:T-bet is pivotal for initiation and perpetuation of Th1 immunity. Identification of novel T-bet regulated genes is crucial for further understanding the biology of this transcription factor. By combining siRNA technology with genome-wide mRNA analysis, we sought to identify new T-bet regulated genes in IL-18-activated KG1 cells. KG1 cells were transfected with either control-siRNA (siRNAc) or siRNA targeting T-bet (siRNA-Tbet) and thereafter stimulated with IL-18. Total RNA was evaluated by genome-wide analysis using the Affymetrix GeneChipÂ® Array System.

2012-10-30 | E-GEOD-37595 | biostudies-arrayexpress

Dnase1l3 enhances antitumor immunity and suppresses tumor progression

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression

| PRJNA803220 | ENA

T-bet-Eomes [ChIP-Seq]

Project description:T-bet-Eomes [ChIP-Seq]

| PRJNA706661 | ENA